CN-15 ADVERSE EFFECTS OF BEVACIZUMAB IN BRAIN TUMOR PATIENTS

BACKGROUND: Bevacizumab is humanized monoclonal antibody inhibiting angiogenesis and the only FDA approved treatment for recurrent glioblastoma. The aim of this study was to look at the occurrence of various adverse effects associated with use of bevacizumab in recurrent glioblastoma. METHODS: In th...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Pawar, Tushar, Ladha, Harshad, Mandel, Jacob, Gilbert, Mark, O'Brien, Barbara, Hamza, Mohamed, Armstrong, Terri
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218009/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou243.15
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky